Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania. The company trades on NGM exchange. The company headquarter is located in Bala Cynwyd, United States.

TickerLRMR
Long NameLarimar Therapeutics, Inc.
Short NameLarimar Therapeutics, Inc.